What drugs does SOLARIS PHARMA CORP make?

SOLARIS PHARMA CORP has 6 FDA-approved drugs including CLINDAMYCIN PHOSPHATE AND TRETINOIN.

What therapeutic areas does SOLARIS PHARMA CORP focus on?

SOLARIS PHARMA CORP focuses primarily on Dermatology and Cardiovascular and 1 other therapeutic areas.

← Back

Data updated: Mar 10, 2026

SOLARIS PHARMA CORP

DermatologyCardiovascularOncology

Generics

SOLARIS PHARMA CORP is a generic drug manufacturer focused on Dermatology, Cardiovascular, Oncology.

2021

Since

Drugs

Trials

120

Approved (2yr)

Key Drugs

CLINDAMYCIN PHOSPHATE AND TRETINOIN

clindamycin phosphate

1 indications · 2015

Recent Activity

METRONIDAZOLE 2026-02-17

Labeling

METRONIDAZOLE 2026-02-17

Labeling

METRONIDAZOLE 2026-02-13

ESTRADIOL 2026-02-02

ESTRADIOL 2026-01-22

Labeling

NITROGLYCERIN 2025-12-18

ESTRADIOL 2025-12-08

TAZAROTENE 2025-11-24

CLINDAMYCIN PHOSPHATE 2025-08-22

Labeling

CLINDAMYCIN PHOSPHATE 2025-08-22

Labeling

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 50%

2 drugs

Cardiovascular 25%

1 drugs

Oncology 25%

1 drugs

Pipeline Strength ProEarly access

Competitors ProEarly access

Baxter specialty

Cardiovascular, Oncology, Dermatology

Bayer big-pharma

Oncology, Cardiovascular, Dermatology

COSETTE other

Cardiovascular, Dermatology, Oncology

FOUGERA PHARMS other

Dermatology, Oncology, Cardiovascular

Pfizer big-pharma

Oncology, Dermatology

SOLARIS PHARMA CORP

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (6)

Active (4)

Discontinued (2)

Company Info